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Background: The tumor suppressor gene E-cadherin gene is frequently silenced in chronic lymphocytic leukemia
(CLL) cells and results in wnt-pathway activation. We analyzed the role of histone epigenetic modifications in
E-cadherin gene silencing.
Methods: CLL specimens were treated with histone deacetylase inhibitor (HDACi) MS-275 and analyzed for
E-cadherin expression with western blot and RT-PCR analysis. The downstream effects of HDACi treated leukemic
cells were studied by analyzing the effect on wnt-pathway signaling. HDACi induced alterations in E-cadherin
splicing were investigated by transcript specific real time PCR analysis.
Results: Treatment of CLL specimens with histone deacetylase inhibitors (HDACi) treatment resulted in an increase
of the E-cadherin RNA transcript (5 to 119 fold increase, n=10) in eight out of ten CLL specimens indicating that
this gene is down regulated by histone hypoacetylation in a majority of CLL specimens. The E-cadherin
re-expression in CLL specimens was noted by western blot analysis as well. Besides epigenetic silencing another
mechanism of E-cadherin inactivation is aberrant exon 11 splicing resulting in an alternatively spliced transcript that
lacks exon 11 and is degraded by the non-sense mediated decay (NMD) pathway. Our chromatin
immunoprecipitation experiments show that HDACi increased the acetylation of histones H3 and H4 in the
E-cadherin promoter region. This also affected the E-cadherin exon 11 splicing pattern as HDACi treated CLL
specimens preferentially expressed the correctly spliced transcript and not the exon 11 skipped aberrant transcript.
The re-expressed E- cadherin binds to β-catenin with inhibition of the active wnt-beta-catenin pathway in these
cells. This resulted in a down regulation of two wnt target genes, LEF and cyclinD1 and the wnt pathway reporter.
Conclusion: The E-cadherin gene is epigenetically modified and hypoacetylated in CLL leukemic cells. Treatment of
CLL specimens with HDACi MS-275 activates transcription from this silent gene with expression of more correctly
spliced E-cadherin transcripts as compared to the aberrant exon11 skipped transcripts that in turn inhibits the wnt
signaling pathway. The data highlights the role of epigenetic modifications in altering gene splicing patterns.
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Wnt pathwayBackground
The wnt-β-catenin pathway is a pro-growth and survival
pathway that is active in multiple tumor types including
chronic lymphocytic leukemia (CLL) [1-3]. Activation of
this pathway in CLL is the result of high wnt and frizzled
expression [4] along with epigenetic down regulation of
wnt pathway antagonist genes including secreted frizzled-
related protein (SFRP) family members, WIF1, DKK3 and* Correspondence: sasharma@mednet.ucla.edu
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reproduction in any medium, provided the orAPC [5,6]. The binding of wnts to their cognate receptors
results in inhibition of GSK3β phosphorylation of β-
catenin and its degradation. Stabilized β-catenin then
translocates to the nucleus and interacts with lymphoid-
enhancing (LEF) and T cell (TCF) transcription factors to
activate transcription of wnt-target genes that include
myc, LEF, cyclinD1, Cox-2, matrix metalloproteinase fam-
ily members etc. [7-11]. E-cadherin expression is also able
to inhibit the β-catenin translocation to the nucleus as its
intracytoplasmic domain binds β- catenin [12,13]. In a
previous study we identified silencing of the E-cadherinl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wnt pathway activation [14] as the ectopic expression of
E-cadherin was sufficient to inhibit the active wnt-β-
catenin pathway. Frequent loss of function of E-cadherin
in CLL specimens and the activation of the wnt pathway
highlights its role in CLL biology [14]. Also as inhibition
of the wnt pathway results in apoptosis of CLL cells this is
an important pathway for developing treatment strategies
for this disease [15,16].
Epigenetic modifications such as DNA methylation
and histone modifications silence a number of genes and
are involved in leukemia initiation and progression
[17,18]. These modifications are heritable, reversible and
alter expression patterns of a number of genes without
altering any DNA sequences. In the case of chronic
lymphocytic leukemia (CLL) a number of genes are re-
portedly silenced by epigenetic alterations including the
wnt pathway inhibitor genes [5,6] and more recently
micro RNA expression was found to be modulated by
epigenetic changes [19]. The inhibitors of these DNA
epigenetic modifications are promising anticancer agents
that allow re- expression of silenced genes, cell cycle ar-
rest and apoptosis [20,21]. Histone deacetylase inhibitors
(HDACi) are an example of drugs that are able to re-
verse epigenetic events and have useful clinical activity
in various hematopoietic malignancies [21-23] including
CLL where exposure to these drugs results significant
apoptosis [24-26]. They increase the acetylation of the
major histones H3 and H4 by inhibiting the histone
deacetylases (HDACs) which leads to change in overall
compactness of the chromatin and promotes accessibil-
ity of the DNA to the transcription factors and gene
transcription [22].
In this report we explored the possibility that E-
cadherin down regulation could be due to epigenetic
modifications and studied the effect of HDACi on CLL
specimens. Our previous report indicates that E-cadherin
down regulation in CLL could be due to excessive aber-
rant splicing resulting in an alternatively spliced, non-
functional E- cadherin transcript that lacks exon 11 of the
gene [14]. This non-functional transcript has a premature
termination codon and is degraded by the NMD pathway
[27,28]. We explored this issue of aberrant splicing in the
HDACi treated CLL specimens as well.
Methods
Cell culture and reagents
CLL specimens were obtained from CLL patients at the
West Los Angeles VA hospital clinic after informed con-
sent and an approval by the West Los Angles VA Medical
Center Institutional Review Board. CLL cells were isolated
by Ficoll-Paque gradient (GE healthcare, Piscataway, NJ)
as manufacturer’s protocol and stored in liquid nitrogen.
Specimens selected for analysis had more than 90% CLLcells in the PBMC isolate. For control samples, peripheral
blood was obtained from four normal donors and PBMC
(peripheral blood mononuclear cells) cells were isolated.
HDACi MS-275 was obtained from ChemieTek, Indian-
apolis, IN and dissolved in DMSO. For HDACi treatment
stored CLL specimens were taken in culture in RPMI1640
media with 10% fetal calf serum (complete media) and
HDACi was added for 48 hours. To inhibit the NMD
pathway and treat CLL cells with HDACi, cells were first
treated with HDACi for 48 hours and emetine was added
at a final concentration of 10μg/ml for the last eight hours.
As a control, cells were treated with emetine alone for 8
hours. Annexin assay for analyzing apoptotic cells after
HDACi treatment was performed with the Annexin V
Apoptosis Detection kit II (BD Pharmingen, CA) as per
manufacturer protocol.
Western blot and immunoprecipitation analysis
For western blot analysis cells were washed with cold
PBS and disrupted in lysis buffer (Cell Signaling, MA)
supplemented with protease inhibitor cocktail (Thermo
Fisher Scientific, MA). They were lysed on ice and then
sonicated for 10 seconds. Insoluble material was removed by
centrifugation (10,000 g, 10 min) and protein concentrations
determined by BioRad DC protein assay (Hercules, CA).
Samples were mixed with SDS sample buffer and 20–30 μg
aliquots resolved on SDS/PAGE gels. Following transfer to
PVDFmembranes immunodetection was performed with E-
cadherin (BD Pharmingen, CA), Ac H3 (06–599, Millipore),
Ac-H4 antibody (sc-34263, Santa Cruz Biotechnology).
Detection was performed with horseradish peroxidase-
conjugated secondary antibodies and chemiluminescence
(ECL plus, GE Healthcare and LAS Mini imager, Fuji).
Immunoprecipitation with beta-catenin antibody (Cell
Signaling, MA) was performed with the Classic IP kit by
(Thermo Fisher Scientific, MA).
Real time PCR and transcript specific PCR analysis
E-cadherin expression in cells was analyzed by real time
PCR analysis. The wild type E-cadherin transcript was
quantified by real time PCR with the 5’ primer
GGATGTGCTGGATGTGAATG that localizes to exon
10 of the E-cadherin gene, the 3’ primer CACAT
CAGACAGGATCAGCAGAA localizes to the exon 12
and the taqman probe TAACATATCGGATTTGGAG
AGAC for the wild type E- cadherin transcript level,
binds to the junction of exon 10-exon 11. The expres-
sion level of the skipped or aberrant transcript (tran-
script lacking exon 11) was determined by a 5’ primer
that is at the junction of exon 10 and 12 (TATGGA
ACAGAAAATAACGTTC) and a 3’ primer in the exon
12 (TGTCATTCACATCAGACAGGAT) with a taqman
probe (AACAGGGACACTTCTG). This primer set only
amplifies the exon 11 skipped or the aberrant transcript.
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by the difference in their Ct values. Taqman probes for
HDAC 1–9, LEF1 and cyclin D1 (Applied Biosystems,
CA) were used to determine their relative expression in
CLL and PBMC cells. Real time PCR for actin expres-
sion was used as a control and relative expression was
determined by the method of Pfall [29].
Chromatin immunoprecipitation assay
ChIP assays were performed according to protocols of
the EZ-ChIPTM Chromatin Immunoprecipitation kit
(Millipore, MA). Briefly, 1×106 CLL cells were fixed with
1% formaldehyde for 10 min at 37°C. The cells were
washed extensively with PBS, and the chromatin was
sheared by sonication (Branson sonicator) to 200–400 bp
fragments. The cross-linked histone-DNA complex was
immunoprecipitated with anti pan Acetylated-H4 (sc-34263,
Santa Cruz Biotechnology), anti pan Acetylated-H3 anti-
bodies (06–599, Millipore). Normal mouse IgG was used as
negative controls. DNA was obtained from the cross-
linked complex and was amplified by a SYBR green based
real-time PCR (Applied Biosystems, CA reagents) with
specific primer sets. Primer sequences will be made avail-
able on request. Data sets were normalized to ChIP input
values. The percent of input DNA immunoprecipitated by
each antibody was calculated using the following method:
% input = 100*2Ctinput – CtIP. (Ct value of input DNA-Ct
value of immunoprecipitated DNA).
Wnt reporter assay
Wnt activity in CLL specimens was determined by a
luciferase reporter assay kit (SABiosciences, CA). This
kit consists of a reporter construct expressing firefly
luciferase with TCF/LEF binding sites and an identical
negative control vector lacking TCF/LEF binding sites.
Both constructs were transfected with a constitutively
active renilla luciferase construct to control for trans-
fection efficiency. CLL cells were thawed, cultured in
complete medium for 24 hours, and then transfected by
the Amaxa protocol (Nucleofector kit V, program U07).
8 hours after transfection cells transfected with the re-
porter construct were split into three wells. One well
was left untreated and the other two were treated with
either HDACi MS-275 (1μM concentration) or the GSK-
3β inhibitor SB-216763 (1μM concentration) for another
24 hours. Cells were then lysed and analyzed by a Dual
luciferase assay (Promega, Madison, WI). Data expressed
as ratios of firefly to renilla to control for transfection
efficiency.
Results
E-cadherin expression with HDAC inhibitors
Inhibition of the histone deacetylase activity is expected
to result in an overall increase in histone acetylation andgene transcription [21]. To test whether E-cadherin ex-
pression in CLL is affected by histone acetylation status,
CLL specimens were treated with HDAC inhibitors
(HDACi). Initially two CLL specimens were treated MS-
275 (Entinostat), a Class 1 HDAC inhibitor at two differ-
ent concentrations for 48 hours and E-cadherin RNA
expression was determined by real time PCR analysis.
Control cells were treated with DMSO alone. Figure 1A
shows the relative fold-increase in E-cadherin RNA ex-
pression (adjusted to actin, mean ± SD) by real time RT-
PCR (untreated sample given an arbitrary value of 1).
The HDACi increased E-cadherin RNA expression in the
two CLL specimens as compared to the DMSO treated
cells. For these two CLL specimens the fold increase in
the E- cadherin RNA expression at 1.0 μM MS-275 con-
centration was between 60 and 150 fold with a smaller in-
duction observed at the 0.1μM concentration.
To determine changes in the global acetylation status
of CLL cells with HDACi treatment, a western blot ana-
lysis was performed. Two CLL specimens were treated
with HDACi MS-275 at two different concentrations of
0.1 and 1.0 μM for 48 hours. Lysates were analyzed with
acetylation specific pan acetyl-H3 and a pan acetyl-H4
antibodies. H3 and H4 are the two major histones that
are post-translationally modified in the cells. As shown
in Figure 1B, there is an increase in the acetylated
histones in the two CLL specimens tested with HDACi
MS-275.
Effect of HDACi on E-cadherin exon 11 splicing
With our finding of an increase in the wild type
E-cadherin transcript (Figure 1A) with exposure to
HDACi, we next investigated whether change in splicing
contributes to this increase in E-cadherin expression
[14]. There is a strong rationale for the HDACi role in
splicing as they alter chromatin structure, increase pro-
moter transcriptional activity and have a role in the se-
lection of alternative exons [30-33]. A transcript specific
real time PCR analysis was performed on HDACi treated
CLL specimens (1.0μM, 48 hours) to quantify the cor-
rectly spliced or wild type transcript and the exon 11
skipped or aberrant transcripts (Figure 2A schematic
and Material and Methods) and the data both for
E-cadherin induction with HDAC MS-275 and the
change in aberrant transcript is shown in Figure 2B
Table. The data in this table represents total transcripts
adjusted to actin and shows that E-cadherin transcript
increases 5 to 119 fold as compared to the non-HDACi
treated CLL cells. A significant specimen to specimen
variation is observed as expected as these are primary
leukemic cells from different CLL patients. In two of the
ten CLL specimens (#9 and #10), no E- cadherin induc-
tion was observed with HDACi exposure. The HDACi
















CLL #1 CLL #2




0.1 M MS-275 1 M MS-275 
Figure 1 Effect of HDAC inhibitors on the E-cadherin transcripts. A. RT-PCR analysis to determine the change in expression of wild type
E-cadherin transcripts with HDACi MS-275 treatment. Two primary CLL specimens were treated with two different concentrations of HDACi
MS-275 (0.1μM and 1.0μM for 48 hours). (Data from two experiments, mean and SD). B. Western blot analysis of two CLL specimens that were
treated with HDACi MS-275 (1μM for 48 hours). Lysates analyzed for acetylated histones H3 (Ac-H3), acetylated histone H4 antibodies (Ac-H4)
with antibodies that recognize the acetylated histones and actin control.
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an increase in wild type E-cadherin expression, the aber-
rant transcript was not detectable by the assay and is
suppressed (CLL#2 and #5). In two CLL specimens
#7and #8 a decrease in the total aberrant transcript was
observed while there is an induction in wild type tran-
script. Three CLL specimens increase the total aberrant
transcript levels with HDACi treatment but in all the
cases, this fold induction is less than the fold induction
of the wild type transcript (CLL#1, #4, #6). Overall the
HDACi exposure increases E-cadherin transcript and
changes the ratio of the two transcripts in a majority of
CLL specimens.
The NMD pathway is constitutively active in all cells in-
cluding CLL specimens degrades the exon 11 skipped aber-
rant transcripts and the data shown above was obtained
with these aberrant RNAs undergoing degradation by this
pathway. Therefore to exclude the possibility that the
changes in aberrant transcript are simply due to HDACi
altering this degradation pathway, experiments were per-
formed with a combination of HDACi and NMD blockade
with a translational inhibitor, emetine to quantify the exon
11 skipped transcripts. Cells were treated with HDACi MS-275 (1.0 μM concentration) for forty eight-hours and emet-
ine was added for the last eight hours of HDACi incubation
to block the NMD followed by transcript specific PCR ana-
lysis. As a control, CLL specimen was treated with emetine
alone for eight hours. Figure 2C,D shows a bar diagram
from CLL #1 and #3, the total transcript levels with eight
hour of emetine only treatment are assigned an arbitrary
expression value of 1. In both the CLL specimens with MS-
275 and emetine exposure we observe a difference in the
induction of the two transcripts as compared to the emet-
ine only treated cells. In CLL#1 (Figure 2C) the wild type
transcript increases by 18-fold with a 5-fold increase in the
aberrant transcript while in CLL specimen #3 (Figure 2D)
interestingly there is a decrease in the total aberrant tran-
script with HDACi treatment with emetine while the wild
type transcript increases four-fold. As the NMD blocker
emetine is toxic to cells the overall induction observed with
HDACi is lower as compared to induction in cells that were
treated with HDACi alone (Figure 2B Table, CLL#1 and
#3). The results demonstrate that the transcriptional induc-
tion with HDACi favors a selective expression of the cor-
rectly spliced E-cadherin transcript in the presence or
absence of the NMD pathway.
Exon 10 Exon 11 Exon 12 










































Fold increase in total wild 
type E-cadherin 
transcript. (mean±SD)
Fold change in total 
aberrant E-cadherin 
transcript
CLL#1 119±12 5 fold increase
CLL#2 56±2.5 undetectable
CLL#3 21±6.5 1.2 fold increase
CLL#4 14±2 6 fold increase
CLL#5 11±4 undetectable
CLL#6 9.8±1.5 4 fold increase
CLL#7 5±0.5 1.3 fold decrease
CLL#8 9.8±1.5 1.3 fold decrease
CLL#9 No induction No change
CLL#10 No induction undetectable
D 
Figure 2 Effect of HDACi on E-cadherin exon 11 splicing. A. Schematic showing the wild type and exon 11 skipped aberrant transcript.
Transcript specific PCR strategy is described in the Material and Methods section. B. Table showing the fold change in E-cadherin wild type RNA
expression and exon 11 skipped RNA expression with HDACi treatment. (Data from at least two experiments for ten primary CLL specimens) C. D.
Effect of NMD inhibition on HDACi mediated induction of transcripts. Two CLL specimens (CLL#1 and #3) were treated with either emetine alone
for 8 hours or with MS-275 (1μM for 48 hours) and in the last 8 hours of MS-275 treatment emetine was added for 8 hours. Bar diagram shows
the change in total transcript levels with MS-275 + emetine treatment as compared to the transcript levels in CLL specimens that were treated
with emetine only.
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Loss of E-cadherin RNA expression in CLL specimens has
been reported earlier [14]. To compare the E- cadherin
expression between normal PBMC cells and CLL cells at
the protein level a western blot analysis was performed.
Figure 3A shows a western blot analysis of three different
PBMC specimens from normal donors. The E-cadherin
expression in PBMC is higher than the low to absent
expression observed in the representative five CLL
specimens shown in Figure 3B (non-treated control). To
confirm that there is also an increase in E-cadherin pro-
tein expression, lysates from HDACi treated (MS-275
treated CLL specimens 1.0 μM, 48 hours) cells were
analyzed for E-cadherin expression. There is a variable E-
cadherin induction observed in all the CLL specimens
tested by western blot analysis (Figure 3B) however in
some cases the increase in expression on the western blot
does not correlate with the fold increase in E-cadherin
RNA expression. The HDACi MS-275 is thus able to re-
express this tumor suppressor gene on both the RNA andprotein level in a majority of CLL specimens and confirms
that the silencing of this gene in CLL is in part due to epi-
genetic histone hypoacetylation.
ChIP analysis of the E-cadherin promoter and HDAC
expression
The western blot analysis (Figure 1) shows a global in-
crease in the acetylated histones when CLL specimens are
treated with HDACi. To further confirm the acetylation
change at the E- cadherin promoter a ChIP analysis was
performed. Two CLL specimens were analyzed with two
different antibodies that only immunoprecipitate the
acetylated histone H3 and H4. E-cadherin promoter and
the exon 11 of the E-cadherin gene were amplified by
PCR with specific primers. The exon 11 region of E-
cadherin was also analyzed by the ChIP assay to determine
whether there are any specific epigenetic alterations that
contribute to improper splicing of this exon. A sensitive
real time PCR strategy was employed to determine the
changes in the immunoprecipitated DNA relative to the
CLL #1 
CLL #2 




















Figure 3 Western Blot analysis for E-cadherin expression in PBMC and CLL specimens. A. Three normal PBMC specimens were analyzed for
E-cadherin expression. B. Western blot analysis of five representative CLL specimens of a total of eight CLL specimens that showed an increase in
E-cadherin RNA. CLL specimens were treated with 1.0μM MS-275 for 48 hours and western blot was performed.
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acetylated histone H3 and H4 are increased at the E-
cadherin promoter region in cells that were treated with
HDACi MS-275 (mean ± SD from two independent
experiments). The results for the exon 11 region ChIP
assay show a smaller increase in acetylated H3 and H4






E-cadherin ChIP analysis 
promoter
Figure 4 Chromatin Immunoprecipitation analysis (ChIP) and HDAC e
Cells were treated with MS-275 at a concentration of 1μM for 24 hours and
antibodies, pan acetyl-H3 and pan acetyl-H4 followed by PCR amplification
performed to determine the percentage of input DNA (mean ± SD, data fr
antibodies B. Real time PCR analysis data on the relative expression level o
also adjusted to actin.indicating that histone acetylation with HDACi are more
pronounced at the E-cadherin promoter region as
compared to the exon 11 region.
Histone hypoacetylation and silencing of the genes is
due to an over expression of HDACs, enzymes that
deacetylate the histones. A number of HDAC genes are












Real time PCR analysis 
xpression analysis. A. ChIP analysis of two CLL specimens (± HDACi).
sheared chromatin immunoprecipitated with two different
of the E-cadherin promoter and exon 11 regions. Real time PCR was
om two experiments) immunoprecipitated by the acetylated histone
f HDAC1-9 in three CLL specimens relative to control PBMC RNA, data
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expression in CLL specimens as compared to normal
PBMC with data adjusted to actin. The data shows that
except for HDAC4, all the other HDAC family of genes
tested are significantly overexpressed in CLL specimens.
Effect of E-cadherin expression on apoptosis and the wnt
pathway
A number of studies have reported that HDACi have
growth inhibitory activity in CLL specimens [23-26] how-
ever the precise mechanism of action of these drugs is not
known. As inhibition of wnt pathway results in apoptosis
in CLL cells and E-cadherin expression inhibits this path-
way [14], we next investigated the effect of HDACi on the
wnt-β-catenin pathway in CLL specimens. E-cadherin
mediated inhibition of the wnt pathway is reportedly due
to its ability to sequestrate β-catenin so to determine
whether this was also the case in CLL, two CLL specimens
were treated with HDACi MS-275 (1μM, twenty-fourA CLL# 1 CLL# 3



























Figure 5 Functional effects of HDACi on CLL specimens A. Two CLL sp
immunoprecipitation analysis was performed. Top panel is an E-cadherin w
HDACi exposure (MS-275 1.0μM, 48 hours). Bottom panel is the western blo
with anti-β-catenin antibody and anti-E-cadherin antibody. E-cadherin prot
from HDACi treated CLL specimen. B. Wnt pathway luciferase reporter assa
or reporter constructs. Reporter transfected cells were separated in three g
shown is a ratio of firefly to renilla. C. Table with real time PCR data with e
MS-275. The numbers represent the percentage decrease in the expression
treated control. D. Induction of apoptosis in CLL specimens with MS-275 tr
concentration of HDACi MS-275 (0.1 and 1.0 μM concentration) and analyz
cytometry based annexin assay. (mean of three experiments).hours). E-cadherin induction was confirmed as shown
earlier (Figure 3B) and in Figure 5A, upper panels. This
lysate was then subjected to immunoprecipitation with an
anti-β-catenin antibody followed by western blot analysis
(Figure 5A lower panel). β-catenin signal was detected in
the immunoprecipitated material in the treated and the
un-treated CLL specimens. We also observed the E-
cadherin protein signal was also detected in the HDACi
treated immunoprecipitate. The results indicate an associ-
ation between the re-expressed E- cadherin and β-catenin
in CLL specimens that are treated with HDACi MS-275.
No E- cadherin or β-catenin signal was observed in the
bead only control immunoprecipitation.
A downstream effect of this sequestration of β-catenin
by E-cadherin is wnt-β- catenin pathway inhibition [1]
and this was further analyzed by a wnt pathway reporter
assay in CLL specimens that were treated with MS-275.
CLL specimens were transiently transfected with the
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eatment. Three CLL specimens were treated with two different
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fold) as compared the control reporter plasmid was
observed (Figure 5B) [4]. As a positive control, transfected
cells were also treated with the compound SB-216763
(1μM concentration), a GSK3β inhibitor that inhibits
GSK3β and increases cellular wnt activity [4]. All the CLL
specimens tested increased the wnt reporter activity in re-
sponse to GSK3β inhibitor providing independent valid-
ation to the wnt reporter assay. The wnt reporter activity
decreased in three of the four CLL specimens that were
treated with MS-275 (1 M for 24 hours) demonstrating
wnt pathway inhibition.
Inhibition of wnt pathway activity due to E-cadherin re-
expression and HDACi exposure is also expected to alter
the expression of wnt pathway target genes. To further
confirm the wnt pathway inhibition, we analyzed two
well-described wnt target genes, LEF (lymphoid enhancing
factor) and cyclinD1 [4] that are also upregulated in CLL.
We first compared the expression of LEF and cyclin D1 in
normal peripheral blood B cells and CLL specimens by
real time PCR analysis. Both these genes were upregulated
in all the CLL specimens tested as compared to peripheral
blood mononuclear B cells (data not shown). CLL
specimens were then treated with HDACi, MS-275 (1 μM
for 48 hours) and analyzed by real time RT-PCR analysis.
LEF expression was downregulated in eight of ten CLL
specimens tested (Figure 5C table). In the case of cyclin
D1, seven out of eight CLL specimens down regulated
cyclin D1 expression (Figure 5C table) when exposed to
HDACi. Downregulation of wnt reporter activity and two
well known wnt target genes with HDACi support the role
of HDACi in the inhibition of the wnt-beta-catenin
pathway.
To further analyze the effect of HDACi on CLL
specimens, an apoptosis assay was performed. Three
CLL specimens were analyzed with a flow cytometry
based annexin V assay. Cells were treated with two dif-
ferent concentrations of HDACi for 48 hours and
analyzed for annexin staining as described. At the 1 m
concentration of MS-275, 30-45% CLL cells were found
to be annexin positive or apoptotic. Similar findings have
been reported with other HDACi as well [23-26]. Overall
the findings indicate an inhibition of the wnt pathway in
CLL specimens with HDACi mediated E-cadherin re-
expression.
Discussion
Our study with primary CLL specimens demonstrates
that the frequent loss of E- cadherin gene expression in
CLL specimens is due to histone epigenetic silencing of
the E-cadherin promoter. This gene silencing can be
reversed by HDACi that acetylate the histones in the
promoter region of this gene and activate E-cadherin
gene transcription. Furthermore this HDACi induced E-cadherin expression inhibits the wnt- β-catenin pathway
in CLL by interacting with β-catenin and thereby
inhibiting its transactivation function. An additional
interesting finding of the study is the effect of HDACi
on E-cadherin splicing as there is a preferential expres-
sion of correctly spliced E-cadherin transcripts.
HDACi increase the E-cadherin expression in a major-
ity of CLL specimens as determined by real time PCR
and this increase in the transcript is also translated into
an increase in E-cadherin signal on the western blot ana-
lysis. The induction of E-cadherin expression by western
blot analysis is variable and a potential reason could be
the pro-apoptotic effect of the HDACi that inhibits pro-
tein translation in some CLL specimens. Lack of re-
sponse to HDACi in two out of ten CLL specimens
could be due to other mechanisms including E-cadherin
promoter methylation that has been reported [34]. With
this significant increase in wild type E-cadherin RNA
transcripts with HDACi we investigated whether there
was a qualitative change in the RNA transcripts as a
number of cellular alterations induced by HDACi such
as gene transcription, change in chromatin structure are
also known to alter gene splicing patterns [30-32].
To study this we analyzed the HDACi treated CLL
specimens for the two E- cadherin transcripts. Analysis
of a number of CLL specimens shows a variable re-
sponse of the exon 11 skipped transcripts to HDACi ex-
posure. In some CLL specimens there is a complete loss
of expression of this transcript and in some cases a de-
crease in expression of aberrant transcript while the total
wild type transcript consistently increased in amount in
the majority of CLL specimens (Figure 2C). In two CLL
specimens the absolute amount of aberrant transcript
also increases with HDACi exposure albeit the fold in-
duction is less than the wild type transcript can be
explained by a more robust HDACi effect on overall E-
cadherin transcription than its ability to alter aberrant
exon 11 splicing. Overall we observe a much smaller in-
crease in the exon 11 skipped transcripts as compared to
the correctly spliced transcript with HDACi exposure.
This change in the ratio of the two transcripts is not due
to a change in the activity of the NMD pathway as
experiments with NMD blocker emetine and HDACi
show similar change in ratios. With NMD blockade as
there is no degradation of the aberrant transcript, both
the transcripts should have a parallel increase in fold in-
duction. The lack of similar fold induction of the two
transcripts in the two CLL specimens with NMD block-
ade supports the argument that with HDACi there is a
qualitative change in splicing pattern along with tran-
scriptional induction.
Histones play an important role in splicing, they are
positioned in a non-random manner on the genome
with a higher concentration at the exon-intron junction
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in the exons as compared to the surrounding introns
[35]. Histone epigenetic alterations are mainly found in
the promoter regions but can also be detected in exonic
regions [36,37]. With more than 95% of genes undergoing
alternative splicing [38,39] in the human genome epigen-
etic histone deacetylation and other modifications such as
methylation in cancer cells can alter splicing for the vast
majority of genes and thereby alter the sequences of many
RNA transcripts. This alteration in splicing can result in
RNA isoforms and proteins with entirely different bio-
logical characteristics and is frequently observed in cancer
cells [40,41]. For example the Bcl-x transcript is alterna-
tively spliced to produce the anti-apoptotic Bcl-x (L) or
the proapoptotic Bcl-x(s) and cancer cells often up re-
gulate the anti-apoptotic Bcl-x (L) isoform which is
associated with reduced sensitivity to chemotherapeutic
drugs [42]. The malignant cells therefore have the ability
to modulate alternative splicing for their growth and sur-
vival advantage.
This change in splicing pattern could be due to many
HDACi effects on the chromatin and gene transcription
[30,31]. There is a change in chromatin compactness
that in turn alters accessibility of DNA to transcription
and splicing factors [22]. It is also plausible that certain
splicing factors are involved in this splicing defect and
their expression is altered by HDACi exposure [43]. Also
as splicing and transcription occur simultaneously,
changes in the transcription with HDACi would affect
splicing as well. As HDACi clearly increase gene tran-
scription of epigenetically silenced genes, this alone
could change the splicing pattern of the E-cadherin
gene. Studies have also shown that rate of transcriptional
elongation can regulate splicing as well [reviewed in 30].
RNA Pol II promoter has a large C-terminal domain
(CTD) that plays a role in splicing as its truncation
results in splicing defects [30]. The CTD is also subject
to regulation by phosphorylation and functions as a
docking protein for splicing factors as well [30].
Differences in Pol II promoter structure thus results in
changes in splicing [44-46]. It is possible that the change
in ratio of the two transcripts observed with HDACi in
CLL specimens is predominantly due to change in E-
cadherin transcription. As the change in transcription
function of the HDACi cannot be separated from its ef-
fect on chromatin compactness and splicing factors, the
precise mechanism by which HDACI induce splicing al-
teration in CLL is not clear.
Mutations of the spliceosome component SF3B1 in CLL
cells have been recently identified in 7.5-15% of CLL
specimens [47]. It is proposed that these mutations could
result in defective spliceosome function, dysregulated spli-
cing, alterations in gene expression and isoform switch.
The precise function of this mutation in CLL is stillunclear but it is known that the mutations are associated
with CLL specimens that are resistant to fludarabine [48].
Further investigation of gene splicing in CLL cells is thus
increasingly important to understand how the various
RNA isoforms affect the biology of CLL and to develop
treatment approaches to modify the splicing.
The role and the mechanism E-cadherin silencing in
hematopoietic cells is not well known. Our findings
clearly indicate that one of the mechanisms of the loss
of its expression is histone hypoacetylation. The HDACi
increase the acetylation of histones in the region of the
E-cadherin promoter as determined by the ChIP assay
and appears that this alteration is more pronounced as
compared to the acetylation change at the exon 11 re-
gion. The overexpression of HDACs in CLL specimens
also supports role of this epigenetic alteration in CLL. A
recent report has analyzed HDAC expression in CLL
specimens and correlated with prognosis [49]. This re-
port also describes upregulation of a number of different
HDAC genes in CLL.
The re-expression of E-cadherin tumor suppressor
gene can have a multitude of effects on tumor cells in-
cluding adhesion, invasion, modulation of receptor kin-
ase activity and wnt pathway activation [50]. These
downstream effects are better defined in the epithelial
cells as compared to the hematopoietic cells. A signaling
pathway in which there is a potential role of E-cadherin
is the wnt pathway and multiple lines of evidence show
that this is an important growth and survival pathway in
CLL [3-6]. Activation of wnt-pathway in CLL results in
up regulation of target genes that are involved in cell
proliferation, survival, adhesion and invasion [51]. The
studies in this report confirm the association between E-
cadherin and β-catenin that is able to sequester beta-
catenin in the cytoplasm which has been reported earlier
in other tumor model systems [12,13]. The HDACi
induced E-cadherin is a thus functional protein and is
able to down regulate the wnt reporter activity in three
out of four CLL specimens tested. There was also a
down regulation of two important downstream effectors
of the wnt pathway, namely LEF and cyclin D1 genes.
The growth inhibition and annexin positivity observed
with HDACi in CLL specimens is thus in part also due
to wnt pathway inhibition.
HDACi reverse the epigenetic modifications, reactivate
gene expression and cause apoptosis in vitro in different
cell types including CLL specimens [23-26]. Our own
studies indicate significant apoptosis of CLL specimens
with the HDACi MS-275. Studies in vivo have been
reported in Tcl1 transgenic mice that develop a disease
similar to CLL patients with elevated B cells, splenomeg-
aly and infiltration of B cells in various organs [52]. The
activity of HDACi AR-42 was tested in a Tcl1 transplant
model and treated mice showed reduction in peripheral
Jordaan et al. BMC Cancer 2013, 13:88 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/88leukocyte counts and survived longer [53]. There are
also encouraging results of clinical trial data in CLL
patients with different HDACi [54]. As these inhibitors
have been approved for treatment of patients with T cell
leukemia [55] and are in clinical trials in other malignan-
cies it is imperative that their mechanism of action is
well understood.
Conclusions
The role of E-cadherin gene that is silenced by epigenetic
alterations and NMD mediated decay was analyzed in
CLL. The silenced E- cadherin gene in CLL can be re-
expressed with HDACi that increase gene transcription
and also preferentially allow the expression of correctly
spliced and functional E-cadherin transcripts. The mech-
anism by which these clinically useful drugs alter splicing
patterns requires further investigations as they are being
used in the treatment of a number of malignancies. The
studies also indicate that besides regulating gene tran-
scription, histone epigenetic modifications could poten-
tially alter gene splicing patterns as well. As large number
of genes are affected by epigenetic alterations in cancer
they can alter splicing and the nature of the transcripts.
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